Zoetis Inc.
$118.25
▲
0.06%
2026-04-22 10:12:13
www.zoetis.com
NYQ: ZTS
Explore Zoetis Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$49.71 B
Current Price
$118.25
52W High / Low
$172.23 / $113.29
Stock P/E
19.63
Book Value
$7.84
Dividend Yield
1.64%
ROCE
27.18%
ROE
65.99%
Face Value
—
EPS
$6.02
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
14,500
Beta
0.97
Debt / Equity
279.59
Current Ratio
3.03
Quick Ratio
1.94
Forward P/E
15.61
Price / Sales
5.26
Enterprise Value
$56.75 B
EV / EBITDA
13.96
EV / Revenue
6
Rating
Buy
Target Price
$151
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Leverage is relatively high.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kamada Ltd. | $8.32 | 23.76 | $479.95 M | 3% | 7.92% | 7.64% | $9.35 / $6.35 | $4.66 |
| 2. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 3. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 4. | Organigram Global Inc. | $1.51 | 15.08 | $274.04 M | — | -3.51% | 4.64% | $3.09 / $1.37 | $1.97 |
| 5. | Amylyx Pharmaceuticals, Inc. | $17.57 | — | $2.03 B | — | -49.46% | -61.59% | $18.61 / $3.79 | $2.78 |
| 6. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 7. | Kiniksa Pharmaceuticals International, plc | $42.46 | 55.07 | $3.25 B | — | 12.37% | 11.73% | $50.03 / $19.62 | $7.44 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2.39 B | 2.4 B | 2.46 B | 2.22 B | 2.32 B | — |
| Operating Profit | 826 M | 936 M | 989 M | 846 M | 765 M | — |
| Net Profit | 603 M | 721 M | 718 M | 631 M | 581 M | — |
| EPS in Rs | 1.43 | 1.71 | 1.71 | 1.5 | 1.38 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 9.47 B | 9.26 B | 8.54 B | 8.08 B |
| Operating Profit | 3.6 B | 3.39 B | 3.07 B | 2.93 B |
| Net Profit | 2.67 B | 2.49 B | 2.34 B | 2.11 B |
| EPS in Rs | 6.36 | 5.91 | 5.57 | 5.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 15.47 B | 14.24 B | 14.29 B | 14.93 B |
| Total Liabilities | 12.14 B | 9.47 B | 9.29 B | 10.52 B |
| Equity | 3.33 B | 4.77 B | 5 B | 4.41 B |
| Current Assets | 6.77 B | 5.99 B | 6.34 B | 7.51 B |
| Current Liabilities | 2.23 B | 3.41 B | 1.89 B | 3.17 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 2.9 B | 2.95 B | 2.35 B | 1.91 B |
| Investing CF | -748 M | -315 M | -777 M | -883 M |
| Financing CF | -1.87 B | -2.66 B | -3.11 B | -904 M |
| Free CF | 2.28 B | 2.3 B | 1.62 B | 1.33 B |
| Capex | -621 M | -655 M | -732 M | -586 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 2.28% | 8.33% | 5.74% | — |
| Earnings Growth % | 7.52% | 6.06% | 10.88% | — |
| Profit Margin % | 28.23% | 26.86% | 27.43% | 26.16% |
| Operating Margin % | 38% | 36.65% | 35.92% | 36.24% |
| Gross Margin % | 71.84% | 70.62% | 70.03% | 69.63% |
| EBITDA Margin % | 42.98% | 41.65% | 42.91% | 41.36% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-01-20 | $0.53 |
| 2025-10-31 | $0.5 |
| 2025-07-18 | $0.5 |
| 2025-04-21 | $0.5 |
| 2025-01-21 | $0.5 |
Stock Splits
No stock split history available.